Clinical trials: Diabetes Type I
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body)properties of FIAsp…
- Trial name
- NCT02003677
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 67 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of Human Insulin to Insulin Inhalation Solution in Children With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the pharmacokinetic profile of two different methods of insulin administration in children with type 1 diabetes.
- Trial name
- NCT00567775
- Testing
- human insulin, inhaled human insulin
- Where
- Denmark
- Volunteers
- 27 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Long-Term Outcomes of Teplizumab in Routine Clinical Care
This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D.
- Trial name
- AL1GN (NCT07360080)
- Testing
- Teplizumab
- Where
- 10 sites in United States, Israel and 1 more
- Volunteers
- 1,000 people
- Sponsor
- Sanofi
Type 1 Diabetes
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)
To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (based on change in HbA1c from baseline to 24 weeks) when administered in combination with mealtime insulin lispro.
- Trial name
- INSTRIDE 1 (NCT02227862)
- Testing
- Mylan's insulin glargine, Lantus®
- Where
- 162 sites in United States, Canada and 9 more
- Volunteers
- 558 people
- Sponsor
- Mylan Inc.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes
This study will investigate how the body processes nasal glucagon and the effect of nasal glucagon on the body. After an 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, the study drug will be…
- Trial name
- NCT02806960
- Testing
- Nasal Glucagon
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Bangladesh
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, complications in diabetic subjects in Asia.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00839878)
- Testing
- No treatment given
- Where
- Bangladesh
- Volunteers
- 2,092 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy
The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are used in insulin pump therapy in adults with type 1 diabetes (T1D).
- Trial name
- PRONTO-Pump-2 (NCT03830281)
- Testing
- Ultra-Rapid Lispro, Insulin Lispro
- Where
- 83 sites in United States, Australia and 9 more
- Volunteers
- 471 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes
The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 1 diabetes (T1D).
- Trial name
- NCT03952130
- Testing
- LY900014, Insulin Lispro, Insulin Glargine
- Where
- 30 sites in Argentina, China and 1 more
- Volunteers
- 354 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
The iLet Experience Study
A one-year, prospective single-arm cohort study to collect safety and effectiveness data on the iLet Dosing Decision Software during real-world use in people 6 years of age or older with type 1 diabetes (T1D) with 12 months…
- Trial name
- NCT06891898
- Testing
- iLet Dosing Decision Software
- Where
- United States
- Volunteers
- 1,875 people
- Sponsor
- Beta Bionics, Inc.
Diabetes, Type I
12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.
The purpose of this study is to compare the safety of HMR 1964 and insulin aspart when used in external pumps with respect to catheter occlusions, GHb assessment, insulin doses, blood glucose parameters, hypoglycemic episodes…
- Trial name
- NCT00046150
- Testing
- Insulin glulisine (HMR1964)
- Where
- 3 sites in France, Germany and 1 more
- Volunteers
- 59 people
- Sponsor
- Sanofi
Diabetes Mellitus
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
To assess the safety and effectiveness of a next-generation automated insulin delivery algorithm in participants aged 16+ years with type 1 or type 2 diabetes.
- Trial name
- Evolution (NCT06181721)
- Testing
- Omnipod 5 Automated Glucose Control System
- Where
- New Zealand
- Volunteers
- 20 people
- Sponsor
- Insulet Corporation
Diabetes Mellitus, Type 1
Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients
·Main objective: To compare the variability of fasting capillary blood glucose concentration, observed with insulin glargine combined with insulin glulisine and with insulin detemir combined with insulin glulisine, in type 1…
- Trial name
- VARIABILITE (NCT00271284)
- Testing
- insulin glulisine / insulin glargine, insulin glulisin / insulin detemir
- Where
- France
- Volunteers
- 88 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes
The trial is conducted in Europe and Africa. The aim of the trial is to compare the use of insulin detemir twice daily combined with mealtime insulin aspart against that of insulin glargine once daily combined with mealtime…
- Trial name
- NCT00312104
- Testing
- insulin detemir, insulin glargine, insulin aspart
- Where
- 46 sites in Austria, Germany and 1 more
- Volunteers
- 325 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus (T1DM)
The Effect of Hedia Diabetes Assistant on TiMe-in-range in People With Type 1 Diabetes and Sub-Optimal Glycemic Control in France - A Randomised Controlled Trial.
The goal of this randomized controlled study is to assess the clinical performance and safety of Hedia Diabetes Assistant in adults with type 1 diabetes and suboptimal glycemic control in France.
- Trial name
- TEMPO (NCT06819306)
- Testing
- Hedia Diabetes Assistant
- Where
- 6 sites in France
- Volunteers
- 154 people
- Sponsor
- Hedia ApS
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes
This study will investigate how the body processes nasal glucagon (NG) and the effect of nasal glucagon on the body. The study is expected to last about 50 days for each participant.
- Trial name
- NCT02806973
- Testing
- Nasal Glucagon
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin
Reason for the study The participants have been diagnosed with type 1 diabetes and are being treated with standard insulin therapy.
- Trial name
- NCT07634770
- Testing
- oral insulin, subcutaneous insulin
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Diabetes Mellitus, Type 1
Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients
This is a sequential efficacy and safety study in pediatric patients with type 1 diabetes. Subjects will be administered insulin to induce a low normal glycemic state and will then receive an age-appropriate dose of G-Pen…
- Trial name
- NCT03091673
- Testing
- Glucagon
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Xeris Pharmaceuticals
Hypoglycemia Unawareness, Diabetes Mellitus, Type 1
Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses
This is a prospective, randomized, controlled, double-blind, parallel 4-group trial with the primary analysis after 4 weeks of treatment with continuous subcutaneous glucagon infusion (CSGI) or placebo.
- Trial name
- NCT03490942
- Testing
- Glucagon
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Xeris Pharmaceuticals
Diabetes, Diabetes Mellitus
French Prospective Multicentric Study in Real World
The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1 Diabetes
- Trial name
- OPTIMAL-A (NCT07039942)
- Testing
- Omnipod 5
- Where
- 24 sites in France
- Volunteers
- 304 people
- Sponsor
- Insulet Corporation
Type 1 Diabetes
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
This is a decentralized observational clinical registry to collect real-world evidence related to the safety and effectiveness of the Omnipod 5 system in children and adults with Type 1 Diabetes.
- Trial name
- NCT06144554
- Testing
- Omnipod 5
- Where
- United States
- Volunteers
- 2,200 people
- Sponsor
- Insulet Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.